Enalare Therapeutics

Focus: Enalare Therapeutics is an early-stage respiratory-focused biotech company founded in 2021, headquartered in Princeton, NJ. The company is publicly listed but remains in early clinical development with no approved products.

Respiratory

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Enalare Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Enalare Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

ENA-001

Respiratory Depression

Phase 1

Clinical Trials (1)

NCT06967259ENA-001 for Opioid Induced Respiratory Depression

Phase 1

Help build intelligence for Enalare Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused therapeutic area (respiratory) with clear clinical unmet need, particularly in respiratory depression management
Public company status provides potential liquidity and institutional credibility versus private-stage peers
Ground-floor opportunity to shape company culture and scientific direction during formative growth phase

Watch Out For

Extremely early pipeline stage (only Phase 1/2 assets) means 7-10+ year horizon to potential product approval and revenue generation
Zero active job postings signals either minimal headcount expansion or hiring pause—limited near-term career mobility
No revenue, limited disclosed financials, and sparse public visibility create uncertainty around cash runway and long-term sustainability

Generated by Claude from Enalare Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

ENA-001

Respiratory Depression

Phase 2

Clinical Trials (1)

NCT06137638ENA-001 for Post Operative Respiratory Depression (PORD)

Phase 2

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Founded: 2021

Portfolio: 2 clinical trials

Top TAs: Neurology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Neurology

2 pipeline

Marketed

Pipeline